pI: 9.6326 |
Length (AA): 171 |
MW (Da): 19920 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
66 | 171 | 1z7p (A) | 3 | 105 | 22.00 | 0 | 1 | 1 | -2.41 |
70 | 171 | 1yka (A) | 1 | 101 | 39.00 | 0 | 1 | 1.3 | -2.27 |
74 | 171 | 2fls (A) | 17 | 111 | 23.00 | 0 | 1 | 1 | -2.76 |
50 | 171 | 2mmz (A) | 1 | 139 | 41.00 | 0 | 1 | 1.09465 | -0.78 |
67 | 171 | 3ipz (A) | 65 | 168 | 41.00 | 0 | 1 | 1.30414 | -2.03 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | Oocyst, Sporozoite. | Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 24 hs, intra-erythrocytic - 32 hs, late trophozoite. | Otto TD PlasmoDB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 16 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, early schizont, early trophozoite, Ring. | Otto TD PlasmoDB Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, Female Gametocyte, Male Gametocyte. | Otto TD Lasonder E |
PlasmoDB | Data on upregulation of P. falciparum genes in different life cycle stages, combined from several microarray experiments available in PlasmoDB |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Ortholog group members (OG5_127295)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G15660 | glutaredoxin 4 |
Arabidopsis thaliana | AT3G54900 | CAX interacting protein 1 |
Babesia bovis | BBOV_IV010730 | hypothetical protein |
Brugia malayi | Bm1_28350 | Hypothetical UPF0055 protein YPL059w |
Candida albicans | CaO19.10298 | glutaredoxin-like orf similar to S. cerevisiae GRX5 (YPL059W) mitochondrial matrix enzyme |
Candida albicans | CaO19.2782 | glutaredoxin-like orf similar to S. cerevisiae GRX5 (YPL059W) mitochondrial matrix enzyme |
Caenorhabditis elegans | CELE_Y49E10.2 | Protein GLRX-5 |
Dictyostelium discoideum | DDB_G0274657 | glutaredoxin-related family protein |
Drosophila melanogaster | Dmel_CG14407 | CG14407 gene product from transcript CG14407-RA |
Escherichia coli | b1654 | glutaredoxin-4 |
Giardia lamblia | GL50803_2013 | Glutaredoxin-related protein |
Homo sapiens | 51218 | glutaredoxin 5 |
Leishmania braziliensis | LbrM.01.0140 | glutaredoxin-like protein |
Leishmania donovani | LdBPK_010110.1 | glutaredoxin-like protein |
Leishmania infantum | LinJ.01.0110 | glutaredoxin-like protein |
Leishmania major | LmjF.01.0110 | glutaredoxin-like protein |
Leishmania mexicana | LmxM.01.0110 | glutaredoxin-like protein |
Loa Loa (eye worm) | LOAG_09509 | hypothetical protein |
Mus musculus | ENSMUSG00000021102 | glutaredoxin 5 homolog (S. cerevisiae) |
Neospora caninum | NCLIV_037620 | Glutaredoxin, related |
Neospora caninum | NCLIV_065200 | hypothetical protein, conserved |
Oryza sativa | 4334801 | Os03g0851200 |
Oryza sativa | 4327130 | Os01g0174900 |
Oryza sativa | 4327794 | Os01g0530400 |
Plasmodium berghei | PBANKA_0403100 | 1-cys-glutaredoxin-like protein-1, putative |
Plasmodium berghei | PBANKA_1219700 | glutaredoxin-like protein |
Plasmodium falciparum | PF3D7_0709200 | glutaredoxin-like protein |
Plasmodium falciparum | PF3D7_0304500 | 1-cys-glutaredoxin-like protein-1 |
Plasmodium knowlesi | PKNH_0838600 | 1-cys-glutaredoxin-like protein-1, putative |
Plasmodium knowlesi | PKNH_0107800 | glutaredoxin-like protein |
Plasmodium vivax | PVX_119350 | 1-cys-glutaredoxin-like protein-1, putative |
Plasmodium vivax | PVX_087990 | glutaredoxin-like protein |
Plasmodium yoelii | PY05059 | glutaredoxin like-protein-related |
Plasmodium yoelii | PY03169 | 1-cys-glutaredoxin-like protein-1 |
Plasmodium yoelii | PY07597 | Plasmodium falciparum CG6 |
Saccharomyces cerevisiae | YPL059W | monothiol glutaredoxin GRX5 |
Schmidtea mediterranea | mk4.000071.06 | Glutaredoxin-related protein 5, mitochondrial |
Trypanosoma brucei gambiense | Tbg972.9.1840 | glutaredoxin-like protein, putative |
Trypanosoma brucei | Tb11.v5.0904 | glutaredoxin-like protein, putative |
Trypanosoma brucei | Tb927.9.3590 | monothiol glutaredoxin, putative |
Trypanosoma congolense | TcIL3000_9_1080 | monothiol glutaredoxin, Grx4 family, putative |
Trypanosoma congolense | TcIL3000_0_30490 | monothiol glutaredoxin, putative |
Trypanosoma cruzi | TcCLB.506893.80 | monothiol glutaredoxin, putative |
Trypanosoma cruzi | TcCLB.508501.230 | monothiol glutaredoxin, putative |
Toxoplasma gondii | TGME49_268730 | glutaredoxin-related protein |
Toxoplasma gondii | TGME49_247580 | glutaredoxin domain-containing protein |
Theileria parva | TP01_0735 | hypothetical protein, conserved |
Theileria parva | TP04_0177 | 1-Cys-glutaredoxin-like protein, putative |
Wolbachia endosymbiont of Brugia malayi | Wbm0676 | glutaredoxin-like protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb09.160.2210 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb09.160.2210 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb09.160.2210 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb09.160.2210 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_Y49E10.2 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_Y49E10.2 | Caenorhabditis elegans | slow growth | wormbase |
PBANKA_1219700 | Plasmodium berghei | Dispensable | plasmo |
TGME49_268730 | Toxoplasma gondii | Essentiality uncertain | sidik |
TGME49_247580 | Toxoplasma gondii | Essentiality uncertain | sidik |
TGME49_268730 | Toxoplasma gondii | Probably essential | sidik |
TGME49_247580 | Toxoplasma gondii | Probably essential | sidik |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.